S.Y. Chui

645 total citations · 1 hit paper
8 papers, 426 citations indexed

About

S.Y. Chui is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Clinical Psychology. According to data from OpenAlex, S.Y. Chui has authored 8 papers receiving a total of 426 indexed citations (citations by other indexed papers that have themselves been cited), including 5 papers in Oncology, 3 papers in Pulmonary and Respiratory Medicine and 2 papers in Clinical Psychology. Recurrent topics in S.Y. Chui's work include Cancer Immunotherapy and Biomarkers (4 papers), Advanced Breast Cancer Therapies (3 papers) and Grit, Self-Efficacy, and Motivation (1 paper). S.Y. Chui is often cited by papers focused on Cancer Immunotherapy and Biomarkers (4 papers), Advanced Breast Cancer Therapies (3 papers) and Grit, Self-Efficacy, and Motivation (1 paper). S.Y. Chui collaborates with scholars based in United States, Germany and Japan. S.Y. Chui's co-authors include Luciana Molinero, Hiroji Iwata, Sylvia Adams, Carlos H. Barrios, Eric P. Winer, Andreas Schneeweiß, Shilpen Patel, Sherene Loi, P. Schmid and Leisha A. Emens and has published in prestigious journals such as Journal of Clinical Oncology, Cancer Research and Nature Chemistry.

In The Last Decade

S.Y. Chui

8 papers receiving 418 citations

Hit Papers

First-line atezolizumab plus nab-paclitaxel for unresecta... 2021 2026 2022 2024 2021 50 100 150 200 250
What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

  1. First-line atezolizumab plus nab-paclitaxel for unresectable, locally advanced, or metastatic triple-negative breast cancer: IMpassion130 final overall survival analysis
    2021 293 citations Leisha A. Emens, Sylvia Adams et al. Annals of Oncology profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
S.Y. Chui United States 7 306 132 110 79 65 8 426
Т. Yu. Semiglazova Russia 7 237 0.8× 79 0.6× 71 0.6× 27 0.3× 24 0.4× 140 367
Byung Kyun Ko South Korea 15 141 0.5× 70 0.5× 127 1.2× 48 0.6× 16 0.2× 37 429
Catherine A. Bingham United States 10 131 0.4× 34 0.3× 101 0.9× 38 0.5× 34 0.5× 17 289
Kate Ingarfield United Kingdom 9 197 0.6× 152 1.2× 95 0.9× 24 0.3× 14 0.2× 17 550
Rosanna Zanetti Switzerland 5 473 1.5× 93 0.7× 78 0.7× 184 2.3× 37 0.6× 6 615
S. Verma Canada 13 217 0.7× 62 0.5× 50 0.5× 26 0.3× 50 0.8× 20 450
Marcus V. Ortega Alves United States 7 192 0.6× 50 0.4× 94 0.9× 26 0.3× 35 0.5× 7 475
Torben Wilms Sweden 12 151 0.5× 52 0.4× 145 1.3× 50 0.6× 10 0.2× 19 379
Peirong Yang United States 7 188 0.6× 37 0.3× 93 0.8× 63 0.8× 15 0.2× 11 403
Ágnes Ruzsa Hungary 6 167 0.5× 115 0.9× 27 0.2× 37 0.5× 14 0.2× 9 301

Countries citing papers authored by S.Y. Chui

Since Specialization
Citations

This map shows the geographic impact of S.Y. Chui's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by S.Y. Chui with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites S.Y. Chui more than expected).

Fields of papers citing papers by S.Y. Chui

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by S.Y. Chui. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by S.Y. Chui. The network helps show where S.Y. Chui may publish in the future.

Co-authorship network of co-authors of S.Y. Chui

This figure shows the co-authorship network connecting the top 25 collaborators of S.Y. Chui. A scholar is included among the top collaborators of S.Y. Chui based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with S.Y. Chui. S.Y. Chui is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

8 of 8 papers shown
1.
Chui, S.Y., et al.. (2024). Engineering a nanoscale liposome-in-liposome for in situ biochemical synthesis and multi-stage release. Nature Chemistry. 16(10). 1612–1620. 24 indexed citations
2.
3.
Emens, Leisha A., Sylvia Adams, Carlos H. Barrios, et al.. (2021). First-line atezolizumab plus nab-paclitaxel for unresectable, locally advanced, or metastatic triple-negative breast cancer: IMpassion130 final overall survival analysis. Annals of Oncology. 32(8). 983–993. 293 indexed citations breakdown →
4.
Harbeck, Nadia, Carlos H. Barrios, Shigehira Saji, et al.. (2020). LBA11 IMpassion031: Results from a phase III study of neoadjuvant (neoadj) atezolizumab + chemotherapy in early triple-negative breast cancer (TNBC). Annals of Oncology. 31. S1144–S1144. 14 indexed citations
5.
Li, William, Ka Yan Ho, Katherine Ka Wai Lam, et al.. (2018). Adventure-based training to promote physical activity and reduce fatigue among childhood cancer survivors: A randomized controlled trial. International Journal of Nursing Studies. 83. 65–74. 65 indexed citations
6.
7.
Ho, Ka Yan, William Li, Katherine Ka Wai Lam, S.Y. Chui, & Gcf Chan. (2015). Psychometric properties of the Chinese version of the fatigue scale-adolescent. BMC Cancer. 15(1). 938–938. 9 indexed citations
8.
Nauman, Deirdre, et al.. (2011). Implementation of a prospective screening tool for breast cancer clinical trial eligibility at an NCI designated cancer center.. Journal of Clinical Oncology. 29(15_suppl). 6052–6052. 1 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Т. Yu. Semiglazova Breakdown of academic impact, for papers by Byung Kyun Ko Breakdown of academic impact, for papers by Catherine A. Bingham Breakdown of academic impact, for papers by Kate Ingarfield Breakdown of academic impact, for papers by Rosanna Zanetti Breakdown of academic impact, for papers by S. Verma Breakdown of academic impact, for papers by Marcus V. Ortega Alves Breakdown of academic impact, for papers by Torben Wilms Breakdown of academic impact, for papers by Peirong Yang Breakdown of academic impact, for papers by Ágnes Ruzsa
Rankless by CCL
2026